l General Information |
Product Name | JNJ-7706621 |
General description | JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2. |
Synonym | 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; JNJ7706621 |
Purity | ≥98.5%(HPLC) | CAS Number | 443797-96-4 |
Formula | C15H12F2N6O3S | Molecular Weight | 394.36 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 (IC50 = 9 nM/4 nM) and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. JNJ-7706621 also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1. |
l Packaging & Storage |
Packaging | 5mg; 10mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
